Neoadjuvant comparisons of aromatase inhibitors and tamoxifen: pretreatment determinants of response and on-treatment effect (Q35586784)

9 August 2017

1 reference

title

Neoadjuvant comparisons of aromatase inhibitors and tamoxifen: pretreatment determinants of response and on-treatment effect (English)

1 reference

9 August 2017

1 reference

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00371-6

3 April 2024

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00371-6

3 April 2024

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00371-6

3 April 2024

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00371-6

3 April 2024

Eric Rosen

1 reference

9 August 2017

Holly Dressman

series ordinal

1 reference

9 August 2017

Jeffery Marks

series ordinal

1 reference

9 August 2017

Matthew J. Ellis

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14623525

3 April 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14623525

3 April 2024

publication date

1 September 2003

1 reference

full work available at URL

9 August 2017

https://api.elsevier.com/content/article/PII:S0960076003003716?httpAccept=text/xml

1 reference

DOI

https://api.crossref.org/works/10.1016/S0960-0760(03)00371-6

https://api.elsevier.com/content/article/PII:S0960076003003716?httpAccept=text/plain

3 April 2024

1 reference

DOI

https://api.crossref.org/works/10.1016/S0960-0760(03)00371-6

The Journal of Steroid Biochemistry and Molecular Biology

3 April 2024

published in

1 reference

9 August 2017

1 reference

9 August 2017

issue

3-5

1 reference

9 August 2017

page(s)

301-307

1 reference

Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900371-6

7 January 2021

Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900371-6

7 January 2021

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900371-6

7 January 2021

Effect of preoperative chemotherapy on the outcome of women with operable breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900371-6

7 January 2021

Underrepresentation of patients 65 years of age or older in cancer-treatment trials

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900371-6

7 January 2021

Progesterone receptors as a prognostic factor in Stage II breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900371-6

7 January 2021

Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900371-6

7 January 2021

Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900371-6

7 January 2021

Oncogene amplification and prognosis in breast cancer: Relationship with systemic treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900371-6

7 January 2021

Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900371-6

7 January 2021

c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900371-6

7 January 2021

Gene expression profiling predicts clinical outcome of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900371-6

7 January 2021

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900371-6

7 January 2021

Predicting the clinical status of human breast cancer by using gene expression profiles

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900371-6

7 January 2021

Genes that co-cluster with estrogen receptor alpha in microarray analysis of breast biopsies

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900371-6

7 January 2021

Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900371-6

7 January 2021

The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-center study

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00371-6

Neoadjuvant endocrine therapy for breast cancer: medical perspectives

3 April 2024

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00371-6

3 April 2024

Identifiers

DOI

1 reference

9 August 2017

1 reference